The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.225 (2.28%)
Spread: 0.80 (8.247%)
Open: 9.875
High: 10.10
Low: 9.875
Prev. Close: 9.875
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell celebrates "positive" clinical trial data for cancer vaccine

Tue, 19th Sep 2023 14:32

(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.

Shares in Scancell were up 20% at 15.75 pence in London on Tuesday afternoon.

The Nottingham, England-based cancer immunotherapies developer said the first stage of its phase 2 Scope trial "[surpassed] its first milestone" with an 82% objective response rate for SCIB1, in combination with checkpoint inhibitors nivolumab and ipilimumab.

Scancell said this compared to a ORR of 50%, with a progression-free survival time of 11.5 months, in patients only receiving nivolumab and ipilimumab. Two patients from the Scope trial reached the 37 weeks evaluation point with an 87% to 94% reduction in total tumour burden.

"We are excited by these highly impressive results for SCIB1 combined with the doublet CPI therapy," said Chief Executive Officer Lindy Durrant. "We thought results from the Phase 1/2 trial evaluating SCIB1 as a monotherapy were positive but results from this combination are even more meaningful."

Durrant added: "Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now one of the most common cancers in young women."

The Scope trial is now in its second stage, and Scancell expects recruitment to complete by the end of this year, and for the data to become available in the first half of 2024.

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more
16 Dec 2019 13:30

Scancell inks AvidiMab agreement with Chinese biotech company

(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.

Read more
16 Dec 2019 09:21

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Read more
12 Dec 2019 14:23

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.